)
)
)
Immunophotonics, Inc. is developing an innovative therapy to prevent cancer from coming back after local tumor destruction (ablation) therapy. Advancements in cancer treatment, such as precision medicines and immune checkpoint inhibitors, have significantly improved cancer patient survival. However, tumor recurrence remains a major challenge for those undergoing curative therapies. The uncertainty of whether cancer will return after treatment weighs heavily on patients and their families. As pioneers of Interventional Immuno-Oncology® Immunophotonics, we are at the forefront of cancer care. The company's goal is to turn local tumor destruction into a systemic immune response that provides long-lasting protection against cancer recurrence. Our proprietary lead molecule, IP-001, is a novel cancer immunotherapy developed by Immunophotonics. It can stimulate the patient's immune system to create a robust defense against cancer following standard tumor ablation therapies.
Year Founded
2012
Expected time of next catalyst update
Next major inflection point anticipated in January 2028.
City
St. Louis
Country
United States
Company CEO or top company official
Miguel Zubizarreta
Development Phase of Primary Product
Phase II
Lead Product in Development
IP-001 is a cationic polymer designed to utilize antigens/tumor debris liberated from approved, traditional interventional oncology procedures (such as tumor ablation) or other methodologies of tumor destruction like radiation therapy, transforming such routine tumor-destruction techniques into a systemic immunotherapy.
Therapeutic Area
Oncology
Website
http://www.immunophotonics.com
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
